ArticleScientific reports2026
Pan-cancer and multi-omics analyses reveal the diagnostic and prognostic value of BAZ2B in cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Bromodomain adjacent to zinc finger domain 2B (BAZ2B) is involved in chromatin remodeling, non-coding RNA regulation, and aging. However, its role in cancer remains unclear. Using multiple databases (TCGA, GEO, GTEx, TIMER2.0, cBioPortal), we found that BAZ2B is downregulated in many cancers, including breast cancer. Low BAZ2B correlates with poor prognosis, immune infiltration, and diagnostic potential, as shown by ROC and Kaplan-Meier analyses. Functionally, BAZ2B knockdown promoted breast cancer cell proliferation, colony formation, migration, and invasion, but suppressed apoptosis. Western blotting showed that BAZ2B depletion decreased Bax and p53, but increased Bcl-2. BAZ2B deficiency increased lactate production and upregulated glycolytic enzymes (LDHA, HK1, HK2, PKM2, PFK1). This suggests BAZ2B suppresses tumors by inhibiting glycolysis. Multi-omics integration further uncovered BAZ2B loss-induced co-activation of pro-inflammatory factor release and mTOR signaling, concurrent with suppression of apoptotic pathways and dysregulation of DNA repair machinery. Clinical validation using tissue microarrays confirmed reduced BAZ2B expression in tumors versus adjacent tissues, consistent with CPTAC proteomic data from UALCAN and immunohistochemical evidence from HPA. Collectively, BAZ2B constrains breast cancer progression by orchestrating proliferation, apoptosis, EMT, and glycolytic metabolism, positioning it as a promising therapeutic target and multi-cancer biomarker.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.